

TDMS No. 20515 - 01

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: RATS/F344/N Tac

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (CIMSTAR 3800)

CAS Number: CIMSTAR3800

Date Report Requested: 10/21/2008

Time Report Requested: 07:18:15

First Dose M/F: 06/12/06 / 06/12/06

Lab: BNW

F1_RD

C Number: C20515
Lock Date: 04/04/2007
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.0.0

TDMS No. 20515 - 01

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: RATS/F344/N Tac

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (CIMSTAR 3800)

CAS Number: CIMSTAR3800

Date Report Requested: 10/21/2008

Time Report Requested: 07:18:15

First Dose M/F: 06/12/06 / 06/12/06

Lab: BNW

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF Metal working fluids (CIMSTAR 3800)

MALE RATS

Organ

Larynx

Larynx: Squamous Epithelium

Liver

Lung: Alveolus

Nose: Goblet Cell

Nose: Olfactory Epithelium

Nose: Respiratory Epithelium

Morphology

Inflammation Chronic

Metaplasia

Hyperplasia

Hepatodiaphragmatic Nodule

Infiltration Cellular Histiocyte

Hyperplasia

Accumulation, Hyaline Droplet

Inflammation

Accumulation, Hyaline Droplet

Inflammation

FEMALE RATS

Organ

Larynx

Larynx: Squamous Epithelium

Liver

Lung: Alveolus

Nose: Goblet Cell

Nose: Olfactory Epithelium

Nose: Respiratory Epithelium

Ovary

Morphology

Inflammation Chronic

Metaplasia

Hyperplasia

Hepatodiaphragmatic Nodule

Inflammation Granulomatous

Infiltration Cellular Histiocyte

Hyperplasia

Accumulation, Hyaline Droplet

Inflammation

Accumulation, Hyaline Droplet

Inflammation

Cyst

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Heart
Cardiomyopathy**

LESION RATES

OVERALL (a)	6/10 (60%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	6/10 (60%)
POLY-3 RATE (b)	6/10.00	0/0.00	0/0.00	0/0.00	0/0.00	6/10.00
POLY-3 PERCENT (g)	60%	0%	0%	0%	0%	60%
TERMINAL (d)	6/10 (60%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	6/10 (60%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.667
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.667
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.667
COCH-ARM / FISHERS	P=0.590	(e)	(e)	(e)	(e)	P=0.675N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=1.000

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Kidney
Nephropathy**

LESION RATES

OVERALL (a)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	7/10 (70%)
POLY-3 RATE (b)	9/10.00	0/0.00	0/0.00	0/0.00	0/0.00	7/10.00
POLY-3 PERCENT (g)	90%	0%	0%	0%	0%	70%
TERMINAL (d)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	7/10 (70%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.292N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.292N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.292N
COCH-ARM / FISHERS	P=0.201N	(e)	(e)	(e)	(e)	P=0.291N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.136N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx
Inflammation Chronic**

LESION RATES

OVERALL (a)	1/10 (10%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	1/10.00	9/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	10%	90%	100%	100%	100%	100%
TERMINAL (d)	1/10 (10%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx
Metaplasia**

LESION RATES

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx: Squamous Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	0/10 (0%)	6/10 (60%)	5/10 (50%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	6/10.00	5/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	60%	50%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	6/10 (60%)	5/10 (50%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P=0.008**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P=0.008**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P=0.008**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.005**	P=0.016*	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Liver
Hepatodiaphragmatic Nodule**

LESION RATES

OVERALL (a)	1/10 (10%)	2/2 (100%)	1/1 (100%)	0/0 (0%)	1/1 (100%)	0/10 (0%)
POLY-3 RATE (b)	1/10.00	2/2.00	1/1.00	0/0.00	1/1.00	0/10.00
POLY-3 PERCENT (g)	10%	100%	100%	0%	100%	0%
TERMINAL (d)	1/10 (10%)	2/2 (100%)	1/1 (100%)	0/0 (0%)	1/1 (100%)	0/10 (0%)
FIRST INCIDENCE	93 (T)	93 (T)	93 (T)	---	93 (T)	---

STATISTICAL TESTS

POLY 3	(e)	P=0.005**	P=0.146	(e)	P=0.146	P=0.500N
POLY 1.5	(e)	P=0.005**	P=0.146	(e)	P=0.146	P=0.500N
POLY 6	(e)	P=0.005**	P=0.146	(e)	P=0.146	P=0.500N
COCH-ARM / FISHERS	P=0.096N	P=0.045*	P=0.182	(e)	P=0.182	P=0.500N
MAX-ISO-POLY-3	(e)	P<0.001**	P=0.022*	(e)	P=0.022*	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Liver
Inflammation Granulomatous**

LESION RATES

OVERALL (a)	0/10 (0%)	0/2 (0%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/2.00	0/1.00	0/0.00	0/1.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/2 (0%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Lung
Inflammation Chronic**

LESION RATES

OVERALL (a)	10/10 (100%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	10/10.00	9/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	100%	90%	100%	100%	100%	100%
TERMINAL (d)	10/10 (100%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)

STATISTICAL TESTS

POLY 3	P=0.488	P=0.500N	(e)	(e)	(e)	(e)
POLY 1.5	P=0.488	P=0.500N	(e)	(e)	(e)	(e)
POLY 6	P=0.488	P=0.500N	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.488	P=0.500N	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.193	P=0.158N	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Lung: Alveolus
Infiltration Cellular Histiocyte**

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	7/10 (70%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	7/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	70%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	7/10 (70%)	10/10 (100%)
FIRST INCIDENCE	---	---	---	---	93 (T)	93 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	P=0.002**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Goblet Cell
Hyperplasia**

LESION RATES

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Olfactory Epithelium
Accumulation, Hyaline Droplet**

LESION RATES

OVERALL (a)	1/10 (10%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	1/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	10%	100%	100%	100%	100%	100%
TERMINAL (d)	1/10 (10%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.003**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Olfactory Epithelium
Inflammation**

LESION RATES

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Respiratory Epithelium
Accumulation, Hyaline Droplet**

LESION RATES

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Respiratory Epithelium
Inflammation**

LESION RATES

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Preputial Gland
Inflammation Chronic**

LESION RATES

OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	2/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	20%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.377	(e)	(e)	(e)	(e)	P=0.500
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.274

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Heart
Cardiomyopathy**

LESION RATES

OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	2/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	20%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
FIRST INCIDENCE	94 (T)	---	---	---	---	94 (T)

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.377	(e)	(e)	(e)	(e)	P=0.500
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.274

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Kidney
Nephropathy**

LESION RATES

OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx
Metaplasia**

LESION RATES

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx: Squamous Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	0/10 (0%)	9/10 (90%)	7/10 (70%)	10/10 (100%)	9/10 (90%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	9/10.00	7/10.00	10/10.00	9/10.00	10/10.00
POLY-3 PERCENT (g)	0%	90%	70%	100%	90%	100%
TERMINAL (d)	0/10 (0%)	9/10 (90%)	7/10 (70%)	10/10 (100%)	9/10 (90%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P=0.002**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Liver
Hepatodiaphragmatic Nodule**

LESION RATES

OVERALL (a)	0/10 (0%)	4/4 (100%)	0/0 (0%)	3/3 (100%)	1/1 (100%)	1/10 (10%)
POLY-3 RATE (b)	0/10.00	4/4.00	0/0.00	3/3.00	1/1.00	1/10.00
POLY-3 PERCENT (g)	0%	100%	0%	100%	100%	10%
TERMINAL (d)	0/10 (0%)	4/4 (100%)	0/0 (0%)	3/3 (100%)	1/1 (100%)	1/10 (10%)
FIRST INCIDENCE	---	94 (T)	---	94 (T)	94 (T)	94 (T)

STATISTICAL TESTS

POLY 3	(e)	P<0.001**	(e)	P=0.003**	P=0.091	P=0.500
POLY 1.5	(e)	P<0.001**	(e)	P=0.003**	P=0.091	P=0.500
POLY 6	(e)	P<0.001**	(e)	P=0.003**	P=0.091	P=0.500
COCH-ARM / FISHERS	P=0.199N	P<0.001**	(e)	P=0.003**	P=0.091	P=0.500
MAX-ISO-POLY-3	(e)	P<0.001**	(e)	P<0.001**	P<0.001**	P=0.158

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Liver
Inflammation Granulomatous**

LESION RATES

OVERALL (a)	3/10 (30%)	0/4 (0%)	0/0 (0%)	0/3 (0%)	0/1 (0%)	6/10 (60%)
POLY-3 RATE (b)	3/10.00	0/4.00	0/0.00	0/3.00	0/1.00	6/10.00
POLY-3 PERCENT (g)	30%	0%	0%	0%	0%	60%
TERMINAL (d)	3/10 (30%)	0/4 (0%)	0/0 (0%)	0/3 (0%)	0/1 (0%)	6/10 (60%)
FIRST INCIDENCE	94 (T)	---	---	---	---	94 (T)

STATISTICAL TESTS

POLY 3	(e)	P=0.307N	(e)	P=0.386N	P=0.689N	P=0.186
POLY 1.5	(e)	P=0.307N	(e)	P=0.386N	P=0.689N	P=0.186
POLY 6	(e)	P=0.307N	(e)	P=0.386N	P=0.689N	P=0.186
COCH-ARM / FISHERS	P=0.033*	P=0.330N	(e)	P=0.420N	P=0.727N	P=0.185
MAX-ISO-POLY-3	(e)	P=0.155N	(e)	P=0.199N	P=0.328N	P=0.089

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Lung
Inflammation Chronic**

LESION RATES

OVERALL (a)	10/10 (100%)	10/10 (100%)	10/10 (100%)	9/10 (90%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	10/10.00	10/10.00	10/10.00	9/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	100%	100%	100%	90%	100%	100%
TERMINAL (d)	10/10 (100%)	10/10 (100%)	10/10 (100%)	9/10 (90%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

STATISTICAL TESTS

POLY 3	P=0.697	(e)	(e)	P=0.500N	(e)	(e)
POLY 1.5	P=0.697	(e)	(e)	P=0.500N	(e)	(e)
POLY 6	P=0.697	(e)	(e)	P=0.500N	(e)	(e)
COCH-ARM / FISHERS	P=0.699	(e)	(e)	P=0.500N	(e)	(e)
MAX-ISO-POLY-3	P=0.282N	(e)	(e)	P=0.158N	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Lung: Alveolus
Infiltration Cellular Histiocyte**

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	100%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	---	---	---	94 (T)	94 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Goblet Cell
Hyperplasia**

LESION RATES

OVERALL (a)	0/10 (0%)	8/10 (80%)	10/10 (100%)	9/10 (90%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	8/10.00	10/10.00	9/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	80%	100%	90%	100%	100%
TERMINAL (d)	0/10 (0%)	8/10 (80%)	10/10 (100%)	9/10 (90%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Olfactory Epithelium
Accumulation, Hyaline Droplet**

LESION RATES

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Olfactory Epithelium
Inflammation**

LESION RATES

OVERALL (a)	0/10 (0%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	9/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	90%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Respiratory Epithelium
Accumulation, Hyaline Droplet**

LESION RATES

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Respiratory Epithelium
Inflammation**

LESION RATES

OVERALL (a)	0/10 (0%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	9/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	90%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Ovary
Cyst**

LESION RATES

OVERALL (a)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/2 (100%)	0/10 (0%)
POLY-3 RATE (b)	2/10.00	0/0.00	0/0.00	0/0.00	2/2.00	0/10.00
POLY-3 PERCENT (g)	20%	0%	0%	0%	100%	0%
TERMINAL (d)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/2 (100%)	0/10 (0%)
FIRST INCIDENCE	94 (T)	---	---	---	94 (T)	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)	P=0.053	P=0.227N
POLY 1.5	(e)	(e)	(e)	(e)	P=0.053	P=0.227N
POLY 6	(e)	(e)	(e)	(e)	P=0.053	P=0.227N
COCH-ARM / FISHERS	P=0.192N	(e)	(e)	(e)	P=0.091	P=0.237N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	P=0.023*	P=0.066N

LEGEND

- (a) Number of tumor-bearing animals/number of animals examined at site.
 - (b) Number of tumor-bearing animals/Poly-3 number
 - (d) Observed incidence at terminal kill.
 - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
 - (e) Value of Statistic cannot be computed.
 - (g) Poly-3 adjusted lifetime tumor incidence.
 - (I) Interim sacrifice
 - (T) Terminal sacrifice
 - # Tumor rates based on numbers of animals necropsied.
 - * To the right of any statistical result, indicates significance at ($P \leq 0.05$).
 - ** To the right of any statistical result, indicates significance at ($P \leq 0.01$).
 - N Indicates a negative trend for all tests
- Logistic regression is an alternative method for analyzing the incidence of non-fatal tumors.
The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***